Straits Times Index
3,300.04 -3.15 (-0.10%) Nikkei
38,432.78 -402.32 (-1.04%) Hang Seng
18,479.37 -98.93 (-0.53%) FTSE 100
8,313.67 +100.18 (+1.22%) Bitcoin USD
62,598.95 -925.07 (-1.46%) CMC Crypto 200
1,297.53 -67.60 (-4.95%)
ABIONYX Pharma SA (ABNX.PA)
- Business Wire
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
PARIS, May 07, 2024--Regulatory News: ABIONYX Pharma (Paris:ABNX):
- Business Wire
ABIONYX Pharma: Availability of the Universal Registration Document for the Year 2023
TOULOUSE, France & LAKELAND, Mich., May 02, 2024--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces that it has filed with the "Autorité des Marchés Financiers" (AMF) its Universal Registration Document for the year ended December 31, 2023, dated April 30, 2024.
- Business Wire
ABIONYX Pharma - Bpifrance Supports the Development of CER-001 in Ophthalmology With a Nearly €1 Million Non-dilutive Innovation Grant
TOULOUSE, France & LAKELAND, Mich., March 14, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces a nearly €1 million innovation grant from Bpifrance. The aim of this grant is to support the development of drug candidate CER-001 in the treatment of a severe indication in ophthalmology.
